MERCK INITIATES TENDER OFFER TO PURCHASE TERNS PHARMACEUTICALS, INC.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy MRK?
Source: moomoo
Merck's Acquisition Move: Merck has initiated a tender offer to acquire Terns Pharmaceuticals, Inc., signaling a strategic expansion in its pharmaceutical portfolio.
Focus on Innovation: The acquisition aims to enhance Merck's capabilities in developing innovative therapies, particularly in the field of oncology and other therapeutic areas.
Financial Details: The tender offer is part of Merck's ongoing strategy to invest in promising biotech firms that align with its long-term growth objectives.
Market Impact: This move is expected to influence the pharmaceutical market dynamics, potentially leading to increased competition and innovation in drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 117.100
Low
95.00
Averages
119.53
High
139.00
Current: 117.100
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
FDA Approves IDVYNSO for HIV Treatment in Adults
- FDA Approval: IDVYNSO has received FDA approval as the first non-INSTI, tenofovir-free, once-daily two-drug regimen, demonstrating non-inferior efficacy compared to the three-drug regimen BIKTARVY, marking a new option in HIV treatment that may enhance patient adherence.
- Clinical Trial Data: In two randomized controlled non-inferiority trials involving 708 HIV patients, only 1% of those on IDVYNSO had HIV-1 RNA ≥50 copies/mL at Week 48, indicating its effectiveness in maintaining viral suppression comparable to BIKTARVY.
- Diverse Patient Population: Among trial participants, 11% were aged 65 and older, showcasing IDVYNSO's applicability in older patients, with similar treatment outcomes across different age, sex, and racial groups, enhancing its market potential.
- Safety and Tolerability: The safety profile of IDVYNSO was comparable to BIKTARVY, with only 3% of patients discontinuing due to adverse events at Week 48, and common side effects like diarrhea and headache were low, indicating good tolerability that may facilitate broader clinical use.
See More
Merck and Eisai's Late-Stage Trial Fails to Meet Goals
- Trial Outcome: The LITESPARK-012 trial conducted by Merck and Eisai failed to meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in kidney cancer patients, which could negatively impact future treatment strategies for both companies.
- Patient Enrollment: Over 1,600 patients were enrolled in the trial, testing various drug combinations including Keytruda and Lenvima, but failed to demonstrate superiority over the already approved Keytruda plus Lenvima regimen, indicating a lack of efficacy for the new therapies.
- Safety Profile: Although the combination therapies did not meet the primary endpoints, the companies noted that their safety profiles were consistent with past results for individual drugs, suggesting no new significant risks emerged, which still holds some value for future clinical applications.
- Market Implications: The failure of this trial may affect Merck's market position in kidney cancer treatment, especially ahead of the Keytruda patent cliff, forcing the company to accelerate other R&D projects to maintain competitiveness.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer
- FDA Priority Review: Pfizer and Astellas announced that the FDA has granted priority review for their marketing application of Padcev in combination with Merck's Keytruda, marking a significant advancement in bladder cancer treatment.
- Indication Expansion: The application aims to expand the use of Padcev with Keytruda to all muscle-invasive bladder cancer patients, not just those ineligible for cisplatin chemotherapy, which is expected to significantly broaden the potential market.
- Clinical Trial Success: This application is based on data from the Phase 3 EV-304 trial, which successfully met its primary endpoint of event-free survival, providing strong support for FDA approval of the therapy.
- Target Action Date: The FDA has set August 17, 2026, as the target action date for the supplemental Biologics License Application, and if approved, it will offer new treatment options for patients, further solidifying Pfizer and Astellas' market position in oncology.
See More
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
FDA Approves IDVYNSO for HIV Treatment in Adults
- FDA Approval: IDVYNSO has received FDA approval as the first non-INSTI, tenofovir-free, once-daily two-drug regimen, demonstrating non-inferior efficacy compared to the three-drug regimen BIKTARVY, marking a new option in HIV treatment that may enhance patient adherence.
- Clinical Trial Data: In two randomized controlled non-inferiority trials involving 708 HIV patients, only 1% of those on IDVYNSO had HIV-1 RNA ≥50 copies/mL at Week 48, indicating its effectiveness in maintaining viral suppression comparable to BIKTARVY.
- Diverse Patient Population: Among trial participants, 11% were aged 65 and older, showcasing IDVYNSO's applicability in older patients, with similar treatment outcomes across different age, sex, and racial groups, enhancing its market potential.
- Safety and Tolerability: The safety profile of IDVYNSO was comparable to BIKTARVY, with only 3% of patients discontinuing due to adverse events at Week 48, and common side effects like diarrhea and headache were low, indicating good tolerability that may facilitate broader clinical use.
See More
Merck and Eisai's Late-Stage Trial Fails to Meet Goals
- Trial Outcome: The LITESPARK-012 trial conducted by Merck and Eisai failed to meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in kidney cancer patients, which could negatively impact future treatment strategies for both companies.
- Patient Enrollment: Over 1,600 patients were enrolled in the trial, testing various drug combinations including Keytruda and Lenvima, but failed to demonstrate superiority over the already approved Keytruda plus Lenvima regimen, indicating a lack of efficacy for the new therapies.
- Safety Profile: Although the combination therapies did not meet the primary endpoints, the companies noted that their safety profiles were consistent with past results for individual drugs, suggesting no new significant risks emerged, which still holds some value for future clinical applications.
- Market Implications: The failure of this trial may affect Merck's market position in kidney cancer treatment, especially ahead of the Keytruda patent cliff, forcing the company to accelerate other R&D projects to maintain competitiveness.
See More
Dagco Increases Sellas Stake to 1.01% Ahead of Key Data
- Stake Increase: Dagco added 451,240 shares of Sellas Life Sciences on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million, making it the second-largest holding at 1.01% of its portfolio, indicating strong confidence in Sellas' future prospects.
- Clinical Data Catalyst: Sellas is set to present preclinical data on SLS009 at the AACR conference, targeting acute myeloid leukemia (AML), with lab studies showing that it induces leukemia cell death by enhancing caspase-3 activity, potentially offering new treatment options for AML patients.
- Regal Trial Progress: The Phase 3 Regal trial has recorded 72 survival events, moving closer to the 80-event threshold for final analysis, with the CEO suggesting that the slower accumulation of events may indicate longer patient survival, further heightening investor expectations.
- Optimistic Market Sentiment: Retail sentiment for SLS on Stocktwits is deemed 'extremely bullish' amid high message volume, with investors generally optimistic about the potential of SLS009, reflecting positive market expectations for Sellas' future developments.
See More
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer
- FDA Priority Review: Pfizer and Astellas announced that the FDA has granted priority review for their marketing application of Padcev in combination with Merck's Keytruda, marking a significant advancement in bladder cancer treatment.
- Indication Expansion: The application aims to expand the use of Padcev with Keytruda to all muscle-invasive bladder cancer patients, not just those ineligible for cisplatin chemotherapy, which is expected to significantly broaden the potential market.
- Clinical Trial Success: This application is based on data from the Phase 3 EV-304 trial, which successfully met its primary endpoint of event-free survival, providing strong support for FDA approval of the therapy.
- Target Action Date: The FDA has set August 17, 2026, as the target action date for the supplemental Biologics License Application, and if approved, it will offer new treatment options for patients, further solidifying Pfizer and Astellas' market position in oncology.
See More
